Document is current
Any future updates will be listed below
-
Authors
Chen, Xuefei https://orcid.org/0009-0006-6304-5777
Koteva, Kalinka https://orcid.org/0000-0002-6446-9567
Chou, Sommer https://orcid.org/0000-0001-7742-7350
Guitor, Allison
Pallant, Daniel https://orcid.org/0000-0003-4402-3637
Lee, Yunjin
Sychantha, David https://orcid.org/0000-0002-3497-1599
French, Shawn https://orcid.org/0000-0002-3565-8385
Hackenberger, Dirk
Robbins, Nicole https://orcid.org/0000-0003-2821-9269
Cook, Michael A.
Brown, Eric D. https://orcid.org/0000-0002-7624-8112
MacNeil, Lesley T.
Cowen, Leah E. https://orcid.org/0000-0001-5797-0110
Wright, Gerard D. https://orcid.org/0000-0002-9129-7131
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (FRN-148463, FRN 143215, PJT-156067, FDN-154288)
Canada Research Chairs (Tier 1, (Tier 1)Microbial Genomics & Infectious Disease)
Foundation for the National Institutes of Health (R01 grant (R01AI127375))
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 25 July 2025
First Online: 8 August 2025
Competing interests
: L.E.C. is a co-founder and shareholder in Bright Angel Therapeutics, a platform company for the development of novel antifungal therapeutics. E.D.B. is the CEO, and L.E.C. and G.D.W. are Science Advisors for Kapoose Creek, a company that harnesses the therapeutic potential of fungi. All other authors declare no competing interests.
